Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CSL Behring